Ittai Harel

Managing Partner, Pitango HealthTech

📍 Other🔄 Updated September 2026💼 3 investments📅 4 years investing🗓 Last invested Apr 2025
VC🌍 Other
3
Total investments
1
Early stage
0
Mid stage
1
Late stage
4y
Years active

Portfolio

3 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Apr 2025
Cellular Intelligence is an AI-native TechBio company building the first universal virtual cell- signaling model to decode and control the complex language of cells. Using our proprietary capsule technology, we generate dynamic cellular data at over 1,000x higher efficiency than existing methods. We train large-scale predictive models on this data to design and optimize regenerative medicine protocols, predict drug responses, and model disease mechanisms. Cellular Intelligence is based in Boston and founded by leading AI entrepreneurs and world-class scientists, engineers, and operators. We are backed by over $62 million from investors like Khosla Ventures and the Chan Zuckerberg Initiative. Follow along as we accelerate breakthroughs across human health.
Board Member
Feb 2024
On a mission to drive an Israeli economic growth engine in HealthTech and accelerate global cure, 8400 The Health Network is weaving a network of HealthTech ecosystem leaders, across silos and sectors, who learn together and create gap-closing projects that will propel a thriving HealthTech industry in Israel. The 8400 Fellowship runs annual cohorts of 60 senior Israeli leaders each, for an intensive 17 day program across 7 months. The program’s tailor-made curriculum is creating a continuous platform for breaking silos, peer learning and designing ecosystem growth initiatives. 8400 fellowship graduates join the 8400 Network.
Board Observer
Apr 2022
SURGE seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed -- focusing 100% of the effective dose at the right place and at the right time. Surgery is the standard of care for most patients with solid tumors, and we are working tirelessly to ensure that nobody grieves the loss of a loved one to preventable post-surgical cancer recurrence.
Experience · 4 entries
All (4)
Investments (3)
Board (2)
2025
Investor
Apr 2025
Cellular Intelligence is an AI-native TechBio company building the first universal virtual cell- signaling model to decode and control the complex language of cells. Using our proprietary capsule technology, we generate dynamic cellular data at over 1,000x higher efficiency than existing methods. We train large-scale predictive models on this data to design and optimize regenerative medicine protocols, predict drug responses, and model disease mechanisms. Cellular Intelligence is based in Boston and founded by leading AI entrepreneurs and world-class scientists, engineers, and operators. We are backed by over $62 million from investors like Khosla Ventures and the Chan Zuckerberg Initiative. Follow along as we accelerate breakthroughs across human health.
2024
Board Member
Feb 2024
On a mission to drive an Israeli economic growth engine in HealthTech and accelerate global cure, 8400 The Health Network is weaving a network of HealthTech ecosystem leaders, across silos and sectors, who learn together and create gap-closing projects that will propel a thriving HealthTech industry in Israel. The 8400 Fellowship runs annual cohorts of 60 senior Israeli leaders each, for an intensive 17 day program across 7 months. The program’s tailor-made curriculum is creating a continuous platform for breaking silos, peer learning and designing ecosystem growth initiatives. 8400 fellowship graduates join the 8400 Network.
2022
Board Observer
Apr 2022
SURGE seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed -- focusing 100% of the effective dose at the right place and at the right time. Surgery is the standard of care for most patients with solid tumors, and we are working tirelessly to ensure that nobody grieves the loss of a loved one to preventable post-surgical cancer recurrence.
2006
Managing General Partner
Jul 2006
Pitango is home to visionary entrepreneurs and groundbreaking companies from stealth mode to growth. We partner with exceptional founding teams via three parallel funds Pitango First, Pitango Growth and Pitango HealthTech.
Investment activity
2022–2025 · 3 investments
202212024120251
Recent (last 2 years)Earlier